Stroke risk in atrial fibrillation
Total Score
Low risk. No anticoagulation needed.
Disclaimer: The clinical scoring and algorithms on this platform are intended strictly for professional informational purposes. They do not constitute a definitive medical diagnosis, treatment, or clinical decision. The final judgment and responsibility lie with the treating physician.
Yasal Uyarı: Bu platformdaki klinik skorlamalar ve algoritmalar yalnızca sağlık profesyonellerini bilgilendirme amaçlıdır. Herhangi bir kesin tıbbi teşhis, tedavi veya klinik karar yerine geçemez. Nihai karar ve sorumluluk hastayı yatak başında değerlendiren hekime aittir.
The CHA2DS2-VASc score is a globally endorsed clinical risk stratification tool used to estimate the annual risk of thromboembolism (stroke, TIA, or systemic embolism) in patients with non-valvular atrial fibrillation. It guides the decision to initiate oral anticoagulation (OAC) therapy according to AHA/ACC and ESC guidelines.
Female sex is a risk modifier rather than an independent risk factor. In current ESC guidelines, a score of 1 in a female (meaning sex is the only risk factor) does not mandate anticoagulation. Treatment is generally considered at a score of ≥1 for men and ≥2 for women, and strongly recommended at ≥2 for men and ≥3 for women.
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.
Disclaimer: The clinical scoring and algorithms on this platform are intended strictly for professional informational purposes. They do not constitute a definitive medical diagnosis, treatment, or clinical decision. The final judgment and responsibility lie with the treating physician.
Apply CHA2DS2-VASc to patients with non-valvular atrial fibrillation to determine whether oral anticoagulation (OAC) is indicated. Per ESC 2020 guidelines: Men with a score ≥ 2 and women with a score ≥ 3 should receive OAC. Men with score 1 and women with score 2 — OAC should be considered after weighing individual bleeding risk (HAS-BLED). Men score 0, women score 1 — do NOT initiate OAC. Note: the female sex category is a 'risk modifier,' not an independent stroke risk factor — a woman with no other risk factors (score = 1 solely for sex) is NOT high-risk.
Prior stroke/TIA/thromboembolism (2 pts) is the single strongest predictor — patients with this history should almost always receive OAC unless there is a specific contraindication. The 'Vascular Disease' criterion includes prior MI, peripheral arterial disease, and aortic plaque. Age ≥ 75 scores 2 points (not 1), reflecting its disproportionate risk contribution. Always calculate CHA2DS2-VASc alongside HAS-BLED — the goal is net clinical benefit, not simply a high AF risk score alone.
Do not apply CHA2DS2-VASc to patients with valvular AF (mitral stenosis, mechanical prosthetic valves) — these patients require anticoagulation regardless of score. The score was derived for NOACs and warfarin decision-making, not antiplatelet therapy; aspirin is no longer recommended as an alternative to OAC in AF. Avoid double-counting: a patient who has had both an MI and a TIA has vascular disease (1 pt) AND stroke history (2 pts) — these are separate criteria.